Darzalex®

SIGN UP LOG IN

MyJanssenCarePath.com

Your Personal Account for online access to:

  • Check your insurance coverage
  • Enroll in Savings Program, if eligible
  • Sign up for treatment support

Paying for DARZALEX®

Paying for DARZALEX®

Helping make DARZALEX® more affordable for eligible patients

At Janssen, we don't want cost to get in the way of treatment you need. We can help you explore options to lower your out-of-pocket cost for DARZALEX®. No matter what type of insurance you have - or even if you don't have insurance - Janssen CarePath can help explain your medication insurance coverage and benefits, and help find programs that may help you pay for DARZALEX®.

If you use commercial or private health insurance to pay for your medication:

Janssen CarePath Savings Program for DARZALEX®

Eligible patients using commercial or private insurance can save on out-of-pocket medication costs for DARZALEX®. Depending on the health insurance plan, savings may apply toward co-pay, co-insurance or deductible. Eligible patients pay $5 per infusion, with a $20,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or any other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. Program does not cover the cost to give you your infusion. See full eligibility requirements.

To learn more, go to your personal Janssen CarePath Account – MyJanssenCarePath.com. If you believe you are eligible for Janssen CarePath Savings Program, go to your account and enroll or call a Janssen CarePath Care Coordinator at 844-55DARZA (844-553-2792).

Call a Janssen CarePath Care Coordinator at 844-55DARZA (844-553-2792) for more information.

If you are using government-funded programs to pay for DARZALEX®:

JanssenPrescriptionAssistance.com provides information on affordability programs and up-to-date information about independent foundations that may have funding available to help you with medication costs for DARZALEX®.

If you are enrolled in Medicare and using Medicare insurance to pay for your medication, our Medicare Resource Guide provides additional information on sources for cost support that may be available for you.

Get Medicare Resource Guide

Call a Janssen CarePath Care Coordinator at 844-55DARZA (844-553-2792) for more information.

If you have no health insurance or no coverage for DARZALEX®:

Janssen CarePath can provide information about independent resources that may be able to help with your out-of-pocket medication costs.

JanssenPrescriptionAssistance.com provides information on affordability programs and up-to-date information about independent foundations that may have funding available to help you with medication costs for DARZALEX®.

Call a Janssen CarePath Care Coordinator at 844-55DARZA (844-553-2792) about affordability programs that may be available.

Other Resources

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, non-profit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if you might qualify for assistance, please contact a JJPAF program specialist at 1-800-652-6227 (9 AM to 6 PM ET) or visit the foundation website at www.JJPAF.org.

What is DARZALEX®?

DARZALEX® is a prescription medicine used to treat multiple myeloma:

  • In combination with the medicines bortezomib, melphalan and prednisone, in people with newly diagnosed multiple myeloma who cannot receive a type of stem cell transplant that uses their own stem cells (autologous stem cell transplant).
  • In combination with the medicines lenalidomide and dexamethasone or bortezomib and dexamethasone, in people who have received at least one prior medicine to treat multiple myeloma.
  • In combination with the medicines pomalidomide and dexamethasone in people who have received at least two prior medicines to treat multiple myeloma, including lenalidomide and a proteasome inhibitor.
  • Alone in people who have received at least three prior medicines to treat multiple myeloma, including a proteasome inhibitor and an immunomodulatory agent, or did not respond to a proteasome inhibitor and an immunomodulatory agent.

It is not known if DARZALEX® is safe and effective in children.

 

Important Safety Information for DARZALEX®

Do not receive DARZALEX® if you have a history of a severe allergic reaction to daratumumab or any of the ingredients in DARZALEX®. See the ingredients for DARZALEX® below.

What should I tell my healthcare provider before taking DARZALEX®?

Before you receive DARZALEX®, tell your healthcare provider about all of your medical conditions, including if you:

  • have a history of breathing problems.
  • have had shingles (herpes zoster).
  • are pregnant or plan to become pregnant. DARZALEX® may harm your unborn baby.
    • Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 3 months after your final dose of DARZALEX®. Talk to your healthcare provider about birth control methods that you can use during this time.
  • are breastfeeding or plan to breastfeed. It is not known if DARZALEX® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX®?

  • DARZALEX® may be given alone or together with other medicines used to treat multiple myeloma.
  • DARZALEX® will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
  • Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
  • Your healthcare provider will give you medicines before each dose of DARZALEX® and after each dose of DARZALEX® to help reduce the risk of infusion reactions.
  • If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of DARZALEX®?

DARZALEX® may cause serious reactions, including:

  • Infusion reactions. Infusion reactions are common with DARZALEX® and can be severe or serious. Your healthcare provider may temporarily stop your infusion or completely stop treatment with DARZALEX® if you have infusion reactions. Get medical help right away if you get any of the following symptoms:
    • shortness of breath or trouble breathing
    • dizziness or lightheadedness (hypotension)
    • cough
    • wheezing
    • throat tightness
    • runny or stuffy nose
    • headache
    • itching
    • nausea
    • vomiting
    • chills
    • fever
  • Changes in blood tests. DARZALEX® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX®. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX®. Tell all of your healthcare providers that you are being treated with DARZALEX® before receiving blood transfusions.
  • Decreases in blood cell counts. DARZALEX® can decrease white blood cell counts which help fight infections and blood cells called platelets which help to clot blood. Your healthcare provider will check your blood cell counts during treatment with DARZALEX®. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.

The most common side effects of DARZALEX® include:

  • tiredness
  • nausea
  • diarrhea
  • shortness of breath
  • trouble sleeping
  • fever
  • cough
  • muscle spasms
  • back pain
  • joint pain
  • vomiting
  • cold-like symptoms (upper respiratory infection)
  • nerve damage causing tingling, numbness or pain
  • swollen hands, ankles or feet
  • constipation
  • chills
  • dizziness

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of DARZALEX®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX® that is written for health professionals.

What are the ingredients in DARZALEX®?
Active ingredient: daratumumab
Inactive ingredients: glacial acetic acid, mannitol, polysorbate 20, sodium acetate trihydrate, sodium chloride, and water for injection

Please see Important Product Information

cp-60860v3